Search results
Results from the 24/7 Vacations Content Network
908 (2024) Website. roivant .com. Footnotes / references. Financials as of 31 March 2024. [update] [1] [2] Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy [3]
Vivek Ganapathy Ramaswamy ( / vɪˈveɪk rɑːməˈswɑːmiː /; [ 1][ 2] vih-VAYK rah-mə-SWAH-mee; born August 9, 1985) is an American entrepreneur. He founded Roivant Sciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared his candidacy for the Republican Party nomination in the 2024 United States presidential election.
Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party ...
Shares of Roivant Sciences, Immunovant's largest shareholder with a 56.5% stake, according to LSEG data, also rose 24.2% to $12.68. ... The positive data from IMVT-1402 could give Roivant another ...
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...
Roivant Sciences said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's ...
Similarly, in 2020, Ramaswamy reduced his stake in Roivant Sciences, with his tax returns showing he made nearly $200 million in a sweet deal with Sumitomo right before the company’s valuation ...
Sumitomo Dainippon Pharma announced a $3B upfront acquisition in September 2019 of five Roivant subsidiaries, including Urovant and Enzyvant. [9] In October 2022, Sumitomo Pharma announced the acquisition of all outstanding shares in Myovant, a former Roivant subsidiary it was previously a majority owner of, valuing the company at $2.9B. [10]